The price of EHAB is predicted to go up -4.05%, based on the high correlation periods with MATH. The similarity of these two price pattern on the periods is 95.59%.
EHAB
MATH
Down: -4.05%Similarity: 95.59%
EHAB Revenue Forecast
EHAB EPS Forecast
EHAB FAQs
What is bull’s view on EHAB?
EHAB stock is currently trading at $7.40, with a recent upgrade to "Strong Buy" by Jefferies, setting a price target of $9.50, reflecting an 8.57% upside. The bull case is supported by the appointment of an experienced CFO and improving financial stability, as seen in its Q3 revenue of $253.6M. Technical indicators suggest a potential resistance at $9.02, aligning with the bullish sentiment.
What is bear's view on EHAB?
EHAB stock currently trades at $7.40, reflecting a bearish sentiment due to weak Q3 earnings with a Non-GAAP EPS of $0.03 and revenue of $253.6M, which failed to excite investors. The stock also dropped 4.5% in pre-market trading on January 3, 2025, indicating continued pressure. Despite a recent CFO appointment and analyst upgrades, the stock's near-term outlook remains cautious due to limited growth catalysts and market skepticism.
What is EHAB revenue forecast for next quarter?
The market consensus for EHAB's revenue in the upcoming quarter is projected to be approximately $266.779M USD.
What is EHAB eps forecast for next quarter?
The market consensus for EHAB's eps in the upcoming quarter is projected to be approximately $0.057 USD.
Jefferies upgraded Enhabit (EHAB) to Buy from Hold with a price target of $9.50, up from $8.25. The company's announcement of a new contract with UnitedHealth (UNH) that pays it a higher rate than its previous agreement eliminates an overhang and execution risk associated with potential revenue and EBITDA losses, the analyst tells investors in a research note. The firm believes the contract should enable Enhabit to focus more on driving growth rather than plugging the potential earnings hole that would have been caused by a UnitedHealth exit.